Sugi Predict

Sugi Predict / Compounds / SCHEMBL1928700

SCHEMBL1928700

SCHEMBL1928700

NC(=O)Nc1cc(-c2ccc(CN3CCOCC3)cc2)sc1C(N)=O

nearest known ligand 0.70

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MAP3K7 O43318 1/20 0.70
▸ CHEK1 O14757 2/20 0.58
▸ IKBKB O14920 9/20 0.57
▸ HDAC1 Q13547 1/20 0.48
▸ PARP1 P09874 1/20 0.47
▸ HRH3 Q9Y5N1 1/20 0.47
▸ HIF1A Q16665 1/20 0.46
▸ EPAS1 Q99814 1/20 0.46
▸ TBK1 Q9UHD2 1/20 0.46
▸ NPC1 O15118 3/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ TP53 P04637 2/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1928109 0.85 CHEK1 (0.80) MAP3K7CHEK1IKBKBSMN1; SMN2
SCHEMBL2928697 0.84 MAP3K7 (0.54) MAP3K7CHEK1HDAC1HRH3HIF1A
SCHEMBL1926925 0.84 IKBKB (0.56) MAP3K7CHEK1IKBKBPARP1HRH3
SCHEMBL7471787 0.83 MAP3K7 (0.62) MAP3K7CHEK1IKBKBPARP1TBK1
SCHEMBL3842698 0.83 MAP3K7 (1.00) MAP3K7CHEK1IKBKB
SCHEMBL1927563 0.82 MAP3K7 (0.64) MAP3K7CHEK1IKBKB
SCHEMBL1927567 0.82 MAP3K7 (0.64) MAP3K7CHEK1IKBKB
SCHEMBL1926780 0.81 CHEK1 (0.81) MAP3K7CHEK1IKBKBSMN1; SMN2
SCHEMBL3510941 0.80 CHEK1 (0.56) MAP3K7CHEK1IKBKBPARP1HRH3
SCHEMBL7478158 0.78 IKBKB (0.60) MAP3K7CHEK1IKBKBHDAC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243403-A1 TREATING COLORECTAL, PANCREATIC, AND LUNG CANCER THE GENERAL HOSPITAL CORPORATION (US) 2014-08-28 — — US claimed
WO-2012166722-A1 TREATING COLORECTAL, PANCREATIC, AND LUNG CANCER THE GENERAL HOSPITAL CORPORATION (US) 2012-12-06 — — WO claimed
US-20110152234-A1 Novel Compounds ASTRAZENECA AB (SE) 2011-06-23 — — US claimed
EP-1421074-B1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2010-09-29 — — EP claimed
US-20070015819-A1 Novel compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2007-01-18 — — US claimed
CN-1263751-C Novel compounds ASTRAZENECA AB (SE) 2006-07-12 — — CN claimed
US-20040242573-A1 Novel compounds ASTRAZENECA AB (SE) 2004-12-02 — — US claimed
CN-1541214-A Novel compounds — 2004-10-27 — — CN claimed
EP-1421074-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2004-05-26 — — EP claimed
WO-2003010158-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2003-02-06 — — WO claimed
US-20250281624-A1 METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES UNIVERSITY OF HOUSTON SYSTEM (US) 2025-09-11 — — US disclosed
EP-4419104-A2 METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES University of Houston System (US) 2024-08-28 — — EP disclosed
CN-118284420-A Methods and compositions for treating chronic inflammatory lesions, metaplasias, dysplasias, and cancers of epithelial tissue 休斯敦大学体系 2024-07-02 — — CN disclosed
WO-2023239422-A2 METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES UNIVERSITY OF HOUSTON SYSTEM (US) 2023-12-14 — — WO disclosed
US-20230233691-A1 METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES UNIVERSITY OF HOUSTON SYSTEM (US) 2023-07-27 — — US disclosed
US-20040242573-A1 Novel compounds ASTRAZENECA AB (SE) 2004-12-02 — — US disclosed
CN-1541214-A Novel compounds — 2004-10-27 — — CN disclosed
WO-2004064775-A2 SIGMA-2 RECEPTOR AGONISTS AND THEIR USE IN THE TREATMENT OF HIV INFECTION THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2004-08-05 — — WO disclosed
EP-1421074-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2004-05-26 — — EP disclosed
WO-2003010158-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2003-02-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250281624-A1 METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES FABP2, MYADM, FABP6 MAP3K7 1978/4885CHEK1 1581/4885IKBKB 431/4885
US-20070015819-A1 Novel compounds CNR1, ABCG2, CNR2 MAP3K7 4034/4885CHEK1 3163/4885IKBKB 3173/4885
US-20040242573-A1 Novel compounds SULT1E1, TPMT, UGT1A1 MAP3K7 4107/4885CHEK1 3264/4885IKBKB 2989/4885
US-20230233691-A1 METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES FABP2, MYADM, FABP6 MAP3K7 1978/4885CHEK1 1581/4885IKBKB 431/4885
US-20110152234-A1 Novel Compounds CNR1, ABCG2, CNR2 MAP3K7 4034/4885CHEK1 3163/4885IKBKB 3173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.